<DOC>
	<DOCNO>NCT02263833</DOCNO>
	<brief_summary>This national study post-marketing surveillance study conduct Korea 29 August 2008 28 August 2012 meet local regulatory requirement Mircera ( monopegylated-epoetin beta ) . Prospective participant-based data collection evaluate safety/risk assessment effectiveness . No specific study-related procedure require . Participants follow long possible physician 's discretion .</brief_summary>
	<brief_title>An Observational , Prospective , Safety Study Mircera ( Monopegylated Epoetin Beta ) Clinical Practice</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<criteria>Adult , age &gt; 18 year Participants stage 35 chronic kidney disease hemodialyzed participant Signed informed consent Current participation clinical study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>